english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's analysis of EMA's transparency policy over the last 10 years: EMA's reply with Prescrire's comments

1 July 2022

In the July-August issue of Prescrire International: Indacaterol + glycopyrronium + mometasone (Enerzair Breezhaler°) in asthma

FREE DOWNLOAD How do Prescrire's editors rate this new fixed-dose combination? And what about the questions raised by a "connected drug" such as the Enerzair Breezhaler°, with its electronic sensor that can record and transmit various data?
Full text available for free download.
1 July 2022

Covid-19: delays in other types of health care

 Editorial  Over 5 million deaths have been directly attributed to the covid-19 pandemic in 2020 and 2021. The estimated number of deaths doubles to quadruples when unrecorded cases and indirect deaths due to the impact of the pandemic on other healthcare services are taken into account.
1 July 2022

Delays in access to EMA documents: the Agency confers with Prescrire

A video conference was held between the European Medicines Agency (EMA) and Prescrire to discuss the delays in dealing with Prescrire's requests for access to documents.
1 July 2022

Intra-articular corticosteroids: risk of rapid destruction of the hip joint

Injection of corticosteroids into the hip joint is aimed at reducing pain and delaying the need for hip replacement. It is possible that, in some patients, these injections cause a rapid exacerbation of their condition.
1 July 2022

Abnormal body odour: drugs can be responsible

Some drugs alter body odour through their own odour, or via their effects on sweat, breath odour, saliva, or the microflora of the skin or mucous membranes.
1 July 2022

Prescrire is taking action at the European level

Via its policy advocacy, Prescrire acts as a force for change in health policies, first and foremost in the interest of patients. Summaries of three such actions undertaken at the European level were published in Prescrire International's July-August issue.
1 July 2022

New! "Top Texts of 2022", from the editors of Prescrire International

1 July 2022

Nirmatrelvir + ritonavir (Paxlovid°) in covid-19, for certain patients at risk of developing severe disease

FEATURED REVIEW The combination of nirmatrelvir + ritonavir (Paxlovid°) is an oral antiviral treatment for adults with covid-19 who have had symptoms for 5 days at most and do not require oxygen therapy, but who have at least one risk factor for developing severe covid-19. How do Prescrire's editors rate this combination in this situation?
Full review (4 pages) available for download by subscribers.
1 June 2022

In the June issue of Prescrire International. Hydroxycarbamide: interstitial lung disease

FREE DOWNLOAD Hydroxycarbamide, alias hydroxyurea, is a cytotoxic drug administered orally in some myeloproliferative syndromes, and to some patients with sickle cell disease to prevent acutely painful vaso-occlusive crises, acute chest syndrome and hospitalisation.
Full text available for free download.
1 June 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90